DR Newell

430 total citations
12 papers, 216 citations indexed

About

DR Newell is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, DR Newell has authored 12 papers receiving a total of 216 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in DR Newell's work include Drug Transport and Resistance Mechanisms (4 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (2 papers). DR Newell is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (2 papers). DR Newell collaborates with scholars based in United Kingdom. DR Newell's co-authors include L Price, AH Calvert, KR Harrap, Alan V. Boddy, A H Calvert, L. R. HUGHES, Steven K. Clinton, Martin O. Leach, J. Glaholm and IE Smith and has published in prestigious journals such as British Journal of Cancer, European Journal of Cancer and British Journal of Clinical Pharmacology.

In The Last Decade

DR Newell

12 papers receiving 211 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
DR Newell United Kingdom 9 108 88 48 34 27 12 216
Peter Nygren Sweden 11 141 1.3× 184 2.1× 37 0.8× 31 0.9× 54 2.0× 14 401
Ricardo Bellott France 9 160 1.5× 123 1.4× 18 0.4× 35 1.0× 25 0.9× 13 329
Mellett Lb 6 112 1.0× 133 1.5× 27 0.6× 35 1.0× 47 1.7× 13 318
Aksana Vasilyeva United States 8 135 1.3× 123 1.4× 41 0.9× 30 0.9× 33 1.2× 13 302
Agneta Freijs Sweden 8 85 0.8× 249 2.8× 29 0.6× 41 1.2× 25 0.9× 9 368
I. Judson United Kingdom 11 119 1.1× 153 1.7× 47 1.0× 52 1.5× 55 2.0× 31 307
Comis Rl United States 6 151 1.4× 190 2.2× 33 0.7× 15 0.4× 60 2.2× 11 337
W J van der Vijgh Netherlands 11 141 1.3× 198 2.3× 85 1.8× 25 0.7× 65 2.4× 11 439
O'Connell Mj United States 10 98 0.9× 195 2.2× 56 1.2× 34 1.0× 42 1.6× 34 318
Madhu B. Garg Australia 11 130 1.2× 243 2.8× 35 0.7× 34 1.0× 51 1.9× 17 394

Countries citing papers authored by DR Newell

Since Specialization
Citations

This map shows the geographic impact of DR Newell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DR Newell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DR Newell more than expected).

Fields of papers citing papers by DR Newell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DR Newell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DR Newell. The network helps show where DR Newell may publish in the future.

Co-authorship network of co-authors of DR Newell

This figure shows the co-authorship network connecting the top 25 collaborators of DR Newell. A scholar is included among the top collaborators of DR Newell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DR Newell. DR Newell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Price, L, et al.. (1998). A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. British Journal of Cancer. 77(12). 2318–2323. 20 indexed citations
2.
Estlin, EJ, Kathryn Balmanno, A H Calvert, et al.. (1997). The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQTM in human leukaemia and colorectal carcinoma cell lines. British Journal of Cancer. 76(12). 1579–1585. 3 indexed citations
3.
Price, L, et al.. (1997). Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. British Journal of Cancer. 76(11). 1466–1473. 24 indexed citations
4.
Peng, Bo, et al.. (1996). Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. British Journal of Cancer. 73(6). 776–780. 29 indexed citations
5.
Newell, DR, et al.. (1993). Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin. British Journal of Cancer. 67(6). 1310–1315. 6 indexed citations
6.
Newell, DR, et al.. (1993). Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. British Journal of Cancer. 67(2). 362–368. 9 indexed citations
7.
Bailey, N P, et al.. (1993). Etoposide phosphate (EP): A comparative intrapatient bio-equivalence study with etoposide(E). European Journal of Cancer. 29. S108–S108. 1 indexed citations
8.
Mansi, J, DR Newell, J. Glaholm, et al.. (1991). A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer. British Journal of Cancer. 64(3). 593–597. 32 indexed citations
9.
Newell, DR, et al.. (1991). The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. British Journal of Cancer. 64(5). 833–838. 34 indexed citations
10.
Newell, DR. (1990). Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations. British Journal of Cancer. 61(2). 189–191. 12 indexed citations
11.
12.
Newell, DR, et al.. (1983). Studies on the pharmacokinetics of chlorambucil and prednimustine in man.. British Journal of Clinical Pharmacology. 15(2). 253–258. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Nygren Breakdown of academic impact, for papers by Ricardo Bellott Breakdown of academic impact, for papers by Mellett Lb Breakdown of academic impact, for papers by Aksana Vasilyeva Breakdown of academic impact, for papers by Agneta Freijs Breakdown of academic impact, for papers by I. Judson Breakdown of academic impact, for papers by Comis Rl Breakdown of academic impact, for papers by W J van der Vijgh Breakdown of academic impact, for papers by O'Connell Mj Breakdown of academic impact, for papers by Madhu B. Garg
Rankless by CCL
2026